1-7 of 7
Michael Lahn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Free
Jennifer Brown, Robert Black, Hang Phan, Katherine Chapis, Samantha Pazienza, Sandra Re, Svitlana Tyekucheva, Inhye Ahn, Matthew S Davids, Lars van der Veen, Michael Lahn, Philippe Armand
Journal: Blood
Blood (2025) 146 (Supplement 1): 3913.
https://doi.org/10.1182/blood-2025-3913
Published: 2025
Journal Articles

Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED)

Free
Alessandro Vannucchi, Chiara Paoli, Paola Guglielmelli, Michael Lahn, Giusy Di Conza, Tracey Hammett, Paramjit Kaur, Jasson Villarreal Hernandez, Mario Tiribelli, Armando Santoro, Matteo Della Porta
Journal: Blood
Blood (2025) 146 (Supplement 1): 3797.
https://doi.org/10.1182/blood-2025-3797
Published: 2025
Journal Articles

The selective PI3Kδ inhibitor roginolisib synergizes with ruxolitinib against progenitor cells from naïve and JAK inhibitor-refractory/resistant patients with myelofibrosis

Free
Manjola Balliu, Valentina Boldrini, Chiara Maccari, Daniele Colazzo, Ilaria Sestini, Giusy Di Conza, Michael Lahn, Paola Guglielmelli, Alessandro Vannucchi
Journal: Blood
Blood (2025) 146 (Supplement 1): 5529.
https://doi.org/10.1182/blood-2025-5529
Published: 2025
Journal Articles

Preclinical Activity of Novel TGF Beta Receptor I Kinase Inhibitors IOA-359 and IOA-360 for Treatment of Anemia in MDS/AML

Free
Nandini Ramachandra, Charan Thej Reddy Vegivinti, Srabani Sahu, Bianca Rivera, Sarah Aminov, Ariel Fromowitz, Jinghang Zhang, Fnu Aodengtuya, Kith Pradhan, Rongbao Zhao, Leya Schwartz, Victor Thiruthuvanathan, Rahul Sanawar, Emma Rabinovich, Opeyemi Ajibade, Aditi Shastri, Michael Lahn, Amit K. Verma
Journal: Blood
Blood (2023) 142 (Supplement 1): 4589.
https://doi.org/10.1182/blood-2023-179921
Published: 2023
Journal Articles

Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma

Free
Carmelo Carlo-Stella, Michael Lahn, Tracey Hammett, Paramjit Kaur, Rebeca Zorrilla, Giusy Di Conza, Lars van der Veen, Catherine Pickering, Armando Santoro
Journal: Blood
Blood (2023) 142 (Supplement 1): 6114.
https://doi.org/10.1182/blood-2023-180671
Published: 2023
Journal Articles

Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies

Free
Binu Kandathilparambil Sasi, Chiara Tarantelli, Elisa Civanelli, Eleonora Cannas, Stacey M Fernandes, Samantha J. Shupe, Michael Lahn, Lars van der Veen, Giusy Di Conza, Francesco Bertoni, Jennifer R. Brown
Journal: Blood
Blood (2023) 142 (Supplement 1): 4179.
https://doi.org/10.1182/blood-2023-180073
Published: 2023
Journal Articles

Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes

Free
David Valcarcel, MD PhD, Amit Verma, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Aristoteles Giagounidis, MD, María Díez-Campelo, MD PhD, Jan Janssen, MD, Richard F. Schlenk, MD, Gianluca Gaidano, MD PhD, Jaime Perez de Oteyza, MD, Ann L Cleverly, MD, Alan Y Chiang, PhD, Michael Lahn, MD, Durisala Desiaih, PhD, Susan C. Guba, MD, Alan F. List, MD, Rami S. Komrokji, MD
Journal: Blood
Blood (2015) 126 (23): 1669.
https://doi.org/10.1182/blood.V126.23.1669.1669
Published: 2015